The WACC of TRYP Therapeutics Inc (TRYP.CN) is 2.7%.
| Range | Selected | |
| Cost of equity | 1.40% - 3.20% | 2.30% |
| Tax rate | 25.90% - 26.50% | 26.20% |
| Cost of debt | 5.00% - 5.00% | 5.00% |
| WACC | 3.4% - 2.0% | 2.7% |
| Category | Low | High |
| Long-term bond rate | 3.2% | 3.7% |
| Equity market risk premium | 5.1% | 6.1% |
| Adjusted beta | -2.83 | -2.83 |
| Additional risk adjustments | 14.5% | 15.0% |
| Cost of equity | 1.40% | 3.20% |
| Tax rate | 25.90% | 26.50% |
| Debt/Equity ratio | 0.36 | 0.36 |
| Cost of debt | 5.00% | 5.00% |
| After-tax WACC | 3.4% | 2.0% |
| Selected WACC | 2.7% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for TRYP.CN:
cost_of_equity (2.30%) = risk_free_rate (3.45%) + equity_risk_premium (5.60%) * adjusted_beta (-2.83) + risk_adjustments (14.75%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.